KRRO Korro Bio, Inc.
USHealthcareAs of 2026-07-10 16:00
Why KRRO matters now
Korro Bio, Inc. (KRRO) is a US stock in Healthcare. The latest InvestLog snapshot shows $14.56 with +1.82% on the session and $144.9M in market capitalization; recent performance reads 1-month +41.97% and YTD +62.17%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-19.6M, and EPS of $-1.69. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -54.6%.
The latest indexable market news headline is "Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $22.00; recent insider activity includes Dolan Oliver filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.26
P/S
33.65
EV/EBITDA
-1.41
DCF Value
$-0.48
FCF Yield
-54.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
73.2%
Operating Margin
-2154.0%
Net Margin
-2954.1%
ROE
-117.9%
ROA
-61.8%
ROIC
-48.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-19.6M | $-1.69 |
| Q4 2025 | $1.3M | $-50.0M | $-5.33 |
| FY 2025 | $6.4M | $-117.3M | $-12.48 |
| Q3 2025 | $1.1M | $-18.1M | $-1.92 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$19.57
Target (Median)
$22.00
Target Range
$10.00 - $30.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
2.10
Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.